Belgian Pediatric Oncology startup Recruits for Brain Tumor Trial

03/05/2016 - 3 minutes

The Belgian biotech startup Oncurious is launching a phase I/IIa trial for an antibody to fight a brain tumor which affects children. 

oncology_neuroblastoma_immunooncology_medulloblastoma_NMTRC_cancerOncurious in Leuven (Belgium) was just launched last April as an emerging oncology company focused orphan drugs for the treatment of pediatric cancers.

Its current candidate is preparing for a phase I/IIa trial for the treatment of relapsed or refractory medulloblastoma – a rare, life-threatening brain tumor that mainly affects children.

It’s the most common pediatric malignant brain tumor, accounting for 20% of all brain tumors in children. In the EU and US around 400 new patients are diagnosed annually, with boys being affected twice as much.

In February, new research on the role of placental growth factor (PlGF) in certain cancers was published in Cell, based on pre-clinical research conducted by the Jain Lab at Massachusetts General Hospital at Harvard (Boston) and Peter Carmeliet’s team at the Vlaams Institute for Biotechnology (VIB) in Flanders.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member